Zenosense, Inc. (ZENO) Well Positioned to Capitalize on Accelerated Market Penetration of Point-of-Care Diagnostics Devices
POC devices speed up triage, diagnosis and treatment of patients MIDS Cardiac™ is being developed to detect the biomarker troponin I or T for suspected heart attack within 3 minutes, as opposed to often taking 60 minutes in central laboratories Global cardiac biomarkers market expected to reach $13.3 billion by 2024 A recent report by Grand View Research analyzes the shortage of skilled medical staff and how this is expected to accelerate the market penetration rate of point-of-care (POC) diagnostic products (http://ibn.fm/6Yb2x). The major advantage of these devices is that they can be operated by both qualified medical professionals and…